Replies to post #36361 on OncoSec Medical Inc (ONCSQ)

[chickpea598]

I think 50% would be a fair assumption. One other thing about the 64%-75% previous data. That data is from the long-term melanoma phase II study with a subset of patients that went on to receive Keytruda. According to Oncosec IR department those patients were not screened with the biomarker assay, which means they may or may not have been non-responders to keytruda monotherapy. So we will only know for sure if we are seeing above average response rates when data is released on Nov. 12th. I think 50% would be a good solid guess though based on previous data and that would be significant indeed.

[hschlauch]

Yeah, I'm also in agreement with Chickpea. A response rate of 64%-75% in the retrospective study is unheard of in metastatic melanoma. Even the toxic yervoy and opdivo combination couldn't reach that level in a SUB-POPULATION of metastatic melanoma patients.

I think it would be hard to get to that level-equivalent (approximately 50% like you mentioned) in the current combination trial, but if it does approach that level of response, then we may be setting a VERY HIGH BAR. The epacadostat and pembrolizumab ECHO 202 phase 1 trial demonstrates the clinical significance and market excitement for successful small trials with widely-applicable treatment platforms. A 50% response rate (in non-responders) is completely unheard of for metastatic melanoma, and on top of that the EP IL-12 platform may work in other indications (e.g. merkel cell, head and neck).